Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Black Diamond Therapeutics, Inc. (BDTX)

Black Diamond posts Q1 net loss of $9.0 million vs. $56.5 million profit a year earlier

Negative Impact 4 of 5 earnings Written later

Black Diamond Therapeutics reported a first-quarter 2026 net loss of $9.0 million, compared with net income of $56.5 million a year earlier. The company recorded no license revenue in the quarter, versus $70.0 million in the first quarter of 2025, and ended March 31, 2026 with $118.3 million in cash, cash equivalents and investments, which it says can fund operations into the second half of 2028.

Key points

  • No license revenue in Q1 2026 versus $70.0 million in Q1 2025
  • Net loss of $9.0 million ($0.16 per share) versus net income of $56.5 million ($1.00 per share basic) a year earlier
  • Cash, cash equivalents and investments of $118.3 million at March 31, 2026, down from $128.7 million at December 31, 2025
  • Oral presentation of silevertinib Phase 2 data scheduled for May 30, 2026 at the ASCO Annual Meeting

The filing

CompanyBlack Diamond Therapeutics, Inc. (BDTX)
Form8-K, current report
Filed with the SECMay 7, 2026, 7:17 AM ET
Accession number0001701541-26-000015

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.